KAER

Biotherapeutics

 

Respiratory Delivery of Biotherapeutics

 

KAER Biotherapeutics™

  • Provides respiratory aerosol delivery services including laboratory and animal studies
  • Partners with pharma and other entities to deliver their biologic and large labile molecules

KAER™ Specializes in the high dose rate delivery of cells, plasmids and large labile molecules, including protiens, surfactant, antibodies, oligonucleotides, anticancer agents and drug carrying matrices.

KAER™ utilizes its proprietary SUPRAER™ aerosol generation and delivery systems to generate highly concentrated aerosols and its Small Animal Exposure System to expose  rats or guinea pigs to these aerosols.

For those diseases that require doses of 10 to 200 mg of medication in the clinic or at home SUPRAER™ has a clear competitive advantage.

Advantages of SUPRAER™ high dose-rate aerosol delivery

  • Targets the drug directly to the diseased lungs
  • Enables home treatment
  • Shortens treatment time
  • Reduces the total dose administered compared to oral or IV
  • Eliminates potential side-effects and complications of long term IV administration
  • Decreases cost of the drug and its administration
  • Increases patient and physician acceptance and compliance
  • Improves therapeutic outcome

 Applications

Spray Drying:


SUPRAER™ is a compact device ideal for spray drying of solutions and suspensions to produce aerosols up to 10 microns in diameter.

Pharmacology:      
Generation of aerosols of pure biologics for tests of efficacy and safety in animals.

Pharmaceutical Agents include:
proteins                    oligonucleotides                
antibodies                 liposomes
surfactant                 vaccines
anticancer agents
slow release matrices

Toxicology
Generation of aerosols of chemicals, environmental agents and toxins for toxicology.
SUPRAER™ and SARES facilitate high level exposures of animals to chemicals and gases.
 

Drug Discovery:
SUPRAER™ and SARES facilitate the discovery and mode of action of new chemical entities

 

 

 

 

 
Copy Right KAER BioTherapeutics Corporation. All Rights Reserved